{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:34:26Z","timestamp":1789014866267,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2021.12.010","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T16:43:31Z","timestamp":1640364211000},"page":"e443-e451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed\/Refractory Follicular Lymphoma and Diffuse Large B\u2010Cell Lymphoma: Results from a Phase 1b Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-8288","authenticated-orcid":false,"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Shivhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4927","authenticated-orcid":false,"given":"Wan-Jen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.12.010_bib0001","first-page":"1","article-title":"Epidemiology and End Results (SEER) cancer statistics database","volume":"2021","year":"2021","journal-title":"Cancer Stat Facts: Non-Hodgkin Lymphoma"},{"key":"10.1016\/j.clml.2021.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.12.010_bib0004","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.12.010_bib0005","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.12.010_bib0006","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 Cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2021.12.010_bib0007","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/CJI.0b013e31816d1d6a","article-title":"B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models","volume":"31","author":"Kim","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.clml.2021.12.010_bib0008","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","article-title":"T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab","volume":"17","author":"Wahlin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.12.010_bib0009","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS Study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0010","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.010_bib0011","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0012","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2021.12.010_bib0013","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cllc.2020.05.008","article-title":"Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung cancer","volume":"21","author":"Chiang","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clml.2021.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.010_bib0016","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0017","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0019","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","article-title":"TIGIT and PD-1 mark intratumoral T cells with reduced effector frunction in B-cell non-Hodgkin lymphoma","volume":"7","author":"Josefsson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2021.12.010_bib0021","doi-asserted-by":"crossref","first-page":"8820377","DOI":"10.1155\/2020\/8820377","article-title":"Activating the antitumor immune response in non-Hodgkin lymphoma using Immune checkpoint inhibitors","volume":"2020","author":"Joshi","year":"2020","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.clml.2021.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"PNAS"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2021.12.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129634","article-title":"Combination of nivolumab, lenalidomide and rituximab in relapsed\/refractory non-germinal center diffuse large B cell lymphoma: Results from a dose-escalation cohort","volume":"134","author":"Sethi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.010_bib0024","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer immunotherapy in diffuse large B-cell lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0026","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell Therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.010_bib0027","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocbtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.010_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.12.010_bib0029","first-page":"40","article-title":"Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T01:41:04Z","timestamp":1668822064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265021024794"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed\/Refractory Follicular Lymphoma and Diffuse Large B\u2010Cell Lymphoma: Results from a Phase 1b Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}